Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented preclinical findings at the Society for Immunotherapy of Cancer Annual Meeting, highlighting the potential of combining selective adenosine A2B and A2A antagonists with cancer vaccines to enhance immune response against tumors [1][2][3] Company Overview - AlphaTON Capital is focused on building a strategic reserve of TON tokens and developing the Telegram ecosystem, providing institutional-grade exposure to the TON ecosystem while maintaining governance standards of a Nasdaq-listed company [7][8] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists targeting A2B and A2A receptors to overcome immune suppression in oncology, with a lead program TT-4 aimed at mesothelioma [10] Clinical Development - The clinical program for TT-4 (A2B receptor antagonist) is preparing for first-patient dosing in Q1 2026, while TT-10 (A2A receptor antagonist) is currently in Phase 1 dose escalation for advanced solid tumors [6] - Preclinical studies demonstrated that the combination of TT-4 and TT-10 with therapeutic vaccines resulted in significant tumor growth suppression and improved survival in mouse models [2][3] Research Collaboration - The collaboration with the National Cancer Institute reflects a multi-year effort to explore the synergistic effects of adenosine receptor antagonists and cancer vaccines, aiming to translate these findings into human applications [3][4]

Dover, DE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (“Cyncado”), today announced a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 5 to 9, 2025, in National Harbor, Maryland. The poster reports preclinical findings from work conducted by investigators at the National Cancer Institute (NCI) at NCI laboratories. In t ...